Subscribe
Sign In
Menu
Search
Financial Times
myFT
Search the
FT
Search
Search the
FT
Search
Close
Home
World
US
Companies
Tech
Markets
Climate
Opinion
Lex
Work & Careers
Life & Arts
HTSI
Sign In
Subscribe
Markets
Markets Data
Equities
Equities Screener
Sectors & Industries
Company Announcements
Director Dealings
World Markets
Financial Times
Close
International Edition
UK Edition
Search the
FT
Search
Top sections
Home
Show more World link
World
Middle East war
Global Economy
UK
US
China
Africa
Asia Pacific
Emerging Markets
Europe
War in Ukraine
Americas
Middle East & North Africa
Show more US link
US
US Economy
US Companies
US Politics & Policy
Show more Companies link
Companies
Energy
Financials
Health
Industrials
Media
Professional Services
Retail & Consumer
Tech Sector
Telecoms
Transport
Show more Tech link
Tech
Artificial intelligence
Semiconductors
Cyber Security
Social Media
Show more Markets link
Markets
Alphaville
Markets Data
Crypto
Capital Markets
Commodities
Currencies
Equities
Monetary Policy Radar
Wealth Management
Moral Money
ETF Hub
Fund Management
Trading
Climate
Show more Opinion link
Opinion
Columnists
The FT View
The Big Read
Lex
Obituaries
Letters
Lex
Show more Work & Careers link
Work & Careers
Business School Rankings
Business Education
Europe's Start-Up Hubs
Entrepreneurship
Recruitment
Business Books
Business Travel
Working It
Show more Life & Arts link
Life & Arts
Arts
Books
Food & Drink
FT Magazine
House & Home
Style
Puzzles
Travel
FT Globetrotter
Show more Personal Finance link
Personal Finance
Property & Mortgages
Investments
Pensions
Tax
Banking & Savings
Advice & Comment
HTSI
Special Reports
FT recommends
Alphaville
FT Edit
Lunch with the FT
FT Globetrotter
#techAsia
Moral Money
Visual and data journalism
Newsletters
Video
Podcasts
News feed
FT Schools
FT Live Events
FT Forums
FT Leaders Academy
myFT
Portfolio
FT Digital Edition
Crossword
Our Apps
My Account
Sign In
Company Announcements
Latest announcements
Apply
Cancel
Filter announcements by
Company
●
Index
View announcements for companies within...
Dow Jones Industrial Average
FTSE 100
FTSE 250
FTSE 350 ACT
FTSE All Share
FTSE Eurofirst 300
NASDAQ Composite
NYSE Composite
S&P 500
Headline contains
●
Release contains
Date range:
Last 24 hours
Last 7 days
Last 28 days
Last 12 months
Custom date
From
To
Sources:
GlobeNewswire
LSE Regulatory News Service
Business Wire press releases
Canada Wire press releases
PR Newswire press releases
EQS Newswire
Countries:
Filter by country
Austria
Belgium
Bosnia and Herzegovina
Croatia
Cyprus
Estonia
Czech Republic
Finland
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Macedonia
Malta
Netherlands
Norway
Poland
Portugal
Romania
Russia
Slovakia
Spain
Sweden
Switzerland
United States
United Kingdom
Turkey
Languages:
Filter by language
Danish
English
Estonian
Finnish
Icelandic
Latvian
Lithuanian
Swedish
Reset filters
Companies:
Index:
Headline contains:
Release contains:
Date range:
Sources:
Countries:
Languages:
Reset filters
Date and time
Company
Headline
Source
07 Dec 2025
Gilead Sciences Inc
GIS:BER
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Business Wire
07 Dec 2025
Genmab A/S
GE9:BER
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma
Business Wire
07 Dec 2025
Prime Medicine Inc
PRME:NMQ
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
GlobeNewswire
07 Dec 2025
ALX Oncology Holdings Inc
ALXO:NSQ
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
GlobeNewswire
07 Dec 2025
Genmab A/S
GE9:BER
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
GlobeNewswire
07 Dec 2025
Molecular Partners AG
MOLN:SWX
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
GlobeNewswire
07 Dec 2025
CARsgen Therapeutics Holdings Ltd
2171:HKG.HS
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
PR Newswire
07 Dec 2025
Akeso Inc
9926:HKG.HS
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
PR Newswire
07 Dec 2025
Zai Lab Ltd
ZLAB:NMQ
Zai Lab Announces Updates to China’s National Reimbursement Drug List
Business Wire
07 Dec 2025
Innovent Biologics Inc
1801:HKG.HZ
Nuvation Equity Warrants Exp 7th July 2027
NUVB WS:NYS
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
PR Newswire
07 Dec 2025
Abbott Laboratories
ABT:NYQ
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
PR Newswire
06 Dec 2025
SK Hynix Inc
HXSCL:PKL
SK hynix Honored with Two Major Titles at GSA Awards 2025
PR Newswire
06 Dec 2025
Pfizer Inc
PFE:NYQ
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
Business Wire
06 Dec 2025
Goldhaven Resources Corp
GHVNF:QBB
Lahontan Gold Corp
LG:CVE
Liberty Gold Corp
LGD:TOR
Scottie Resources Corp
SCOT:CVE
West Red Lake Gold Mines Ltd
WRLG:CVE
Resource Growth Programs Gain Momentum as Gold Holds Above $4,200
PR Newswire
06 Dec 2025
TScan Therapeutics Inc
TCRX:NMQ
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire
06 Dec 2025
Fulcrum Therapeutics Inc
FULC:NMQ
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
GlobeNewswire
RNS announcements are delayed by up to an hour.
Fewer results
1
2
3
...
498
499
500
More results